CD274 and non-small cell lung carcinoma: PD-L1 expression should be systematically determined in advanced NSCLC, and PD-L1 testing is required for first-line pembrolizumab and atezolizumab monotherapy, as well as second-line pembrolizumab (level of evidence I, A) [27].